Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate
- PMID: 31119966
- DOI: 10.1080/10428194.2019.1612061
Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate
Abstract
Peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) are rare, heterogeneous non-Hodgkin lymphomas with poor prognoses. Pralatrexate has demonstrated efficacy in T-cell lymphomas; however, mucositis has been reported as the most common dose-modifying adverse event. Leucovorin has been shown to minimize mucositis incidence, without sacrificing pralatrexate efficacy. We retrospectively studied 34 patients (7-PTCL/27-CTCL) treated with pralatrexate alone or pralatrexate and leucovorin. Leucovorin was administered preemptively prior to any mucositis occurrence. Pralatrexate dosing ranged from 10-30 mg/m2 and clinical response or disease stabilization was observed in 85.2%. The incidence of mucositis was reduced in CTCL patients to 17% and was ameliorated in all but one patient with PTCL. There was no change the incidence of skin reactions with the addition of leucovorin. The response rates were similar to those previously reported in CTCL and PTCL. The addition of leucovorin reduced the incidence of mucositis in patients with CTCL and PTCL.
Keywords: Mucositis; cutaneous T-cell lymphoma; leucovorin; peripheral T-cell lymphoma; pralatrexate; skin reactions.
Similar articles
-
Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy.Leuk Lymphoma. 2013 Nov;54(11):2448-51. doi: 10.3109/10428194.2013.779688. Epub 2013 Apr 8. Leuk Lymphoma. 2013. PMID: 23442065 Free PMC article.
-
Pralatrexate (Folotyn).Skinmed. 2012 Jul-Aug;10(4):244-6. Skinmed. 2012. PMID: 23008944
-
Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.Expert Rev Hematol. 2020 Jun;13(6):577-583. doi: 10.1080/17474086.2020.1756257. Epub 2020 Apr 26. Expert Rev Hematol. 2020. PMID: 32293930 Review.
-
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.Blood. 2012 May 3;119(18):4115-22. doi: 10.1182/blood-2011-11-390211. Epub 2012 Mar 6. Blood. 2012. PMID: 22394596 Clinical Trial.
-
Pralatrexate for Peripheral T-Cell Lymphoma (PTCL): Chance Only Supports The Prepared Mind.Anticancer Agents Med Chem. 2023;23(3):298-305. doi: 10.2174/1871520622666220610151603. Anticancer Agents Med Chem. 2023. PMID: 35692151 Review.
Cited by
-
Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro.Front Cell Dev Biol. 2020 Oct 9;8:577215. doi: 10.3389/fcell.2020.577215. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33163492 Free PMC article.
-
Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes.Curr Oncol Rep. 2020 Apr 16;22(5):44. doi: 10.1007/s11912-020-00902-1. Curr Oncol Rep. 2020. PMID: 32297075 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical